Federal Register / Vol. 86, No. 37 / Friday, February 26, 2021 / Notices 11777 

1617148601?pwd=eVBTM0dweHFx

QUxWUzU2OEttY1R1QT09, webinar ID: 

161 714 8601, and passcode: v08w0@e5. 

FOR FURTHER INFORMATION CONTACT: 

Staci Morris, Committee Management 

Specialist, National Center for HIV, 

Viral Hepatitis, STD, and TB 

Prevention, CDC, 1600 Clifton Road NE, 

Mailstop US8–6, Atlanta, Georgia 

30329–4027, Telephone: (404) 718– 

7479; smorris4@cdc.gov. 

SUPPLEMENTARY INFORMATION: Time will 

be available for public comment. The 

public is welcome to submit written 

comments in advance of the meeting. 

Comments should be submitted in 

writing by email to the contact person 

listed below by Monday, April 19, 2021. 

Persons who desire to make an oral 

statement, may request it at the time of 

the public comment period on April 20, 

2021 at 4:25 p.m., EDT. 

Purpose: This committee is charged 

with advising the Director, CDC, and the 

Administrator, HRSA, regarding 

activities related to prevention and 

control of HIV, Viral Hepatitis and other 

STDs, the support of health care 

services to persons living with HIV, and 

education of health professionals and 

the public about HIV, Viral Hepatitis 

and other STDs. 

Matters To Be Considered: The agenda 

will include discussions on (1) STI 

Screening and Diagnostics; (2) 

Innovation and COVID–19; and (3) 

Youth and Mental Health. Agenda items 

are subject to change as priorities 

dictate. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–03962 Filed 2–25–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

CDC/HRSA Advisory Committee on 

HIV, Viral Hepatitis and STD Prevention 

and Treatment (CHACHSPT) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC and the Health Resources and 

Services Administration (HRSA) 

announce the following meeting for the 

CDC/HRSA Advisory Committee on 

HIV, Viral Hepatitis and STD Prevention 

and Treatment (CHACHSPT). This 

business meeting is open to the public, 

limited only by audio and web 

conference lines (1000 audio and web 

conference lines are available). The 

public is welcome to listen to the 

meeting by accessing the telephone 

number 1–669–254–5252, and the 

passcode is 55572151 (1000 lines are 

available). The web conference access is 

https://cdc.zoomgov.com/j/

1606419940?pwd=

V2krVkVXbGtvVFdLbX

V3N25PbTV4UT09, webinar ID: 160 641 

9940 and passcode: ZeTt@2VL. 

DATES: The business meeting will be 

held on April 12, 2021, from 3:00 p.m. 

to 5:00 p.m., EDT. 

ADDRESSES: The teleconference access is 

1–669–254–5252, and the passcode is 

55572151. The web conference access is 

https://cdc.zoomgov.com/j/ 

1606419940?pwd=V2krVkVXbGtvV

FdLbXV3N25PbTV4UT09, webinar ID: 

160 641 9940 and passcode: ZeTt@2VL. 

FOR FURTHER INFORMATION CONTACT: 

Staci Morris, Committee Management 

Specialist, National Center for HIV, 

Viral Hepatitis, STD, and TB 

Prevention, CDC, 1600 Clifton Road NE, 

Mailstop US8–6, Atlanta, Georgia 

30329–4027, Telephone (404) 718–7479; 

smorris4@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: This committee is charged 

with advising the Director, CDC and the 

Administrator, HRSA, regarding 

activities related to prevention and 

control of HIV, Viral Hepatitis and other 

STDs, the support of health care 

services to persons living with HIV/ 

AIDS, and education of health 

professionals and the public about HIV, 

Viral Hepatitis and other STDs. 

Matters To Be Considered: The agenda 

will include discussions on (1) HIV 

Testing Guidelines; and (2) FDA 

reclassification, home-based HIV selftests and point-of-care testing for HCV. 

Agenda items are subject to change as 

priorities dictate. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–03961 Filed 2–25–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Clinical Laboratory Improvement 

Advisory Committee (CLIAC). This 

meeting is open to the public, limited 

only by the webcast lines available. 

Check the CLIAC website on the day of 

the meeting for the web conference link 

www.cdc.gov/cliac. 

DATES: The meeting will be held on 

April 14, 2021, from 11:00 a.m. to 6:00 

p.m., EDT and April 15, 2021, from 

11:00 a.m. to 6:00 p.m., EDT. 

ADDRESSES: This is a virtual meeting. 

Meeting times are tentative and subject 

to change. The confirmed meeting 

times, agenda items, and meeting 

materials including instructions for 

accessing the live meeting broadcast 

will be available on the CLIAC website 

at www.cdc.gov/cliac. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Anderson, MMSc, MT (ASCP), 

Senior Advisor for Clinical Laboratories, 

Division of Laboratory Systems, Center 

for Surveillance, Epidemiology and 

Laboratory Services, Office of Public 

Health Scientific Services, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop V24–3, 


khammond on DSKJM1Z7X2PROD with NOTICES